PPA
RLMD icon

Parametric Portfolio Associates’s Relmada Therapeutics RLMD Stock Holding History

Parametric Portfolio Associates’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$529K Buy
+19,618
New +$406K ﹤0.01% 3074
2021
Q4 		– Sell
-18,117
Closed -$475K – 3687
2021
Q3 		$475K Buy
+18,117
New +$485K ﹤0.01% 3132

Other funds holding RLMD

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Parametric Portfolio Associates's RLMD Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Relmada Therapeutics (RLMD) in Q1 2022: 19,618 shares worth $529K. The stake represents ﹤0.01% of the portfolio and ranks #3074 among its holdings. This is a return to the name: Parametric Portfolio Associates previously reported a position in RLMD as recently as Q3 2021.

Parametric Portfolio Associates first reported a position in RLMD in Q3 2021 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold RLMD as of Q1 2022.

  • Parametric Portfolio Associates held 19,618 shares of Relmada Therapeutics worth $529K as of Q1 2022.
  • Relmada Therapeutics was a new Parametric Portfolio Associates position in Q1 2022.
  • Relmada Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3074 holding.
  • Parametric Portfolio Associates first reported a position in Relmada Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.